Cas:68784-69-0 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene manufacturer & supplier

Chemical Name:4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene

CAS.NO:68784-69-0

Synonyms:EINECS 272-267-3;4,4′-(1-Methylethylidene)bisphenol,2-methyl-1-propene,ethenylbenzene reaction product;Phenol,4,4′-(1-methylethylidene)bis-,reaction products with isobutylene and styrene

Molecular Formula:C₂₇H₃₂O₂

Molecular Weight:388.54200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:400.8ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:40.46000

Exact Mass:388.24000

LogP:7.33570

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like EINECS 272-267-3 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phenol,4,4′-(1-methylethylidene)bis-,reaction products with isobutylene and styrene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenol,4,4′-(1-methylethylidene)bis-,reaction products with isobutylene and styrene Use and application,EINECS 272-267-3 technical grade,usp/ep/jp grade.

Related News: ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene supplier ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene vendor In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol,2-methylprop-1-ene,styrene factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.